Novo Nordisk announced last week that it plans to invest approximately 16 billion Danish kroner in GLP-1 drug production. That equates to about $2.32 billion or €2.14 billion.
The company plans to expand its Chartres, France, production site for its current and future product portfolio within serious chronic diseases. This investment significantly increases the capacity of the manufacturing site. It adds aseptic production and finished production processes and extends its current quality control laboratory.
Denmark-based Novo Nordisk’s investment doubles the footprint of the existing plant. It began construction projects and expects finalization between 2026 and 2028, with more than 500 new jobs set to come along with it.
The company said its investment ups the capacity for GLP-1 products and will help it meet future demands for innovative medicine.
GLP-1 receptor agonists, like Ozempic and Wegovy, provide therapy for diabetes and weight loss. This therapeutic class, a glucagon-like peptide 1, has proven to lead to improved blood sugar control and weight loss. The drugs have made major waves in the pharmaceutical and medical markets over the past year or so.
“This significant investment announced today confirms the importance of our French manufacturing site, one of our strategic production sites, as a cornerstone of the growth we are experiencing as a company. By maximising the skills and infrastructure we already have on the site, we are expanding our capacity in an efficient way,” said Lone Charlotte Larsen, corporate VP of Novo Nordisk Production Chartres.